EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis

Luc E Coffeng iD, Matthew Graham, Raiha Browning, Klodeta Kura, Peter J Diggle, Matthew Denwood, Graham F Medley, Roy M Anderson, Sake J de Vlas

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Luc E Coffeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Schistosoma mansoni, Schistosomiasis mansoni, Parasite Egg Count. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Bill & Melinda Gates Foundation, NTD Modelling Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Control of schistosomiasis (SCH) relies on the regular distribution of preventive chemotherapy (PC) over many years. For the sake of sustainable SCH control, a decision must be made at some stage to scale down or stop PC. These “stopping decisions” are based on population surveys that assess whether infection levels are sufficiently low. However, the limited sensitivity of the currently used diagnostic (Kato-Katz [KK]) to detect low-intensity infections is a concern. Therefore, the use of new, more sensitive, molecular diagnostics has been proposed.

Methods

Through statistical analysis of Schistosoma mansoni egg counts collected from Burundi and a simulation study using an established transmission model for schistosomiasis, we investigated the extent to which more sensitive diagnostics can improve decision making regarding stopping or continuing PC for the control of S. mansoni.

Results

We found that KK-based strategies perform reasonably well for determining when to stop PC at a local scale. Use of more sensitive diagnostics leads to a marginally improved health impact (person-years lived with heavy infection) and comes at a cost of continuing PC for longer (up to around 3 years), unless the decision threshold for stopping PC is adapted upward. However, if this threshold is set too high, PC may be stopped prematurely, resulting in a rebound of infection levels and disease burden (+45% person-years of heavy infection).

Conclusions

We conclude that the potential value of more sensitive diagnostics lies more in the reduction of survey-related costs than in the direct health impact of improved parasite control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisSchistosoma mansoniSchistosomiasis mansoniParasite Egg CountHumansAnimalsAnthelminticsFemaleMaleSchistosomiasisAdultAdolescentChildChemopreventionYoung AdultSensitivity and Specificity

Stichwörter der Autor:innen

bilharziacost-efficiencydecision criteriondiagnostic performancefecal smear

Substanzen

Anthelmintics

Autor:innen und Institutionen

  • Department of Public Health, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands.
  • Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford.
  • Department of Statistics, University of Warwick.
  • London Centre for Neglected Tropical Disease Research, School of Public Health, Imperial College London.
  • Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London.
  • Centre for Health Informatics, Computing, and Statistics, Lancaster University Medical School, United Kingdom.

ORCID-Profile: Luc E Coffeng

Förderung

  • Medical Research Council
  • Bill & Melinda Gates Foundation
  • NTD Modelling Consortium
  • MRC Centre for Global Infectious Disease Analysis
  • UK Medical Research Council
  • UK Foreign, Commonwealth and Development Office
  • FCDO

Zitieren

APA

Coffeng, L. E., Graham, M., Browning, R., Kura, K., Diggle, P. J., Denwood, M., Medley, G. F., Anderson, R. M., & de Vlas, S. J. (2024). Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae020

Vancouver

Coffeng LE, Graham M, Browning R, Kura K, Diggle PJ, Denwood M, et al. Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae020

BibTeX
@article{Coffeng2024,
  author = {Coffeng, Luc E and Graham, Matthew and Browning, Raiha and Kura, Klodeta and Diggle, Peter J and Denwood, Matthew and Medley, Graham F and Anderson, Roy M and de Vlas, Sake J},
  title = {Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae020}
}
Kostenlos starten →